In breast cancer with BRCA1/2 mutation, olaparib or talazoparib has significantly prolonged PFS in OLYMPIAD [12] and EMBRACA [13] trials of metastatic setting, respectively, and olaparib has significantly improved invasive disease-free survival and overall survival (OS) in OLYMPIA trial of adjuvant setting [14, 15]. Here, BRCA1 is linked to breast cancer.